Table 2.
Post hoc tests for clinical and pathological characteristics which were found to significantly differ between the HER2-negative, HER2-low, and HER2-positive primary breast tumours using the Bonferroni method.
| HER2-negative vs. HER2-low tumours | HER2-negative vs. HER2-positive tumours | HER2-low vs. HER2-positive tumours | |
|---|---|---|---|
| Unifocal tumour | |||
| P values | 0.107 | <0.001 | <0.001 |
| Histology | |||
| P values | 0.189 | 0.009 | <0.001 |
| Tumour Size | |||
| P values | 0.013 | 0.055 | 0.919 |
| E&E grade | |||
| P values | 0.581 | 0.002 | 0.003 |
| Nuclear grade | |||
| P values | 0.015 | 0.001 | <0.001 |
| Lymph node status | |||
| P values | 0.024 | 0.033 | 0.169 |
| Disease stage | |||
| P values | 0.162 | <0.001 | 0.016 |
| Oestrogen receptor expression | |||
| P values | 0.015 | <0.001 | <0.001 |
| Progesterone receptor expression | |||
| P values | 0.025 | <0.001 | <0.001 |
| Time to recurrence | |||
| P values | 0.643 | 0.007 | 0.039 |
E&E Elston and Ellis, HER2 human epidermal growth factor receptor 2.
Values in bold italic show statistically significant P-values.